Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Roy Taylor BSc, MB ChB, MD, FRCP, FRCPE

Roy Taylor BSc, MB ChB, MD, FRCP, FRCPE

Professor of Medicine and Metabolism, Magnetic Resonance Centre, Campus for Ageing and Vitality, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom

Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine at Newcastle University. He founded the Newcastle Magnetic Resonance Centre in 2006 to develop innovative research techniques. Using these new techniques, in 2011 he showed that type 2 diabetes was a simple, reversible condition of excess fat within liver and pancreas. Subsequent he has clarified what causes type 2 diabetes and how it works. This has led to practical application in the national ‘NHS Type 2 Diabetes Path to Remission’ programme as part of the NHS.

Between 1986 and 2000, Professor Taylor developed the system now used throughout the United Kingdom for screening for diabetic eye disease, with major reduction in blindness due to diabetes across the UK.

He has published books in lay language explaining type 2 diabetes (eg ‘Life Without Diabetes’) and his named lectures include the 2012 Banting Lecture of Diabetes UK and the 2015 Harry Keen Lecture. In 2023 he was awarded the Robert Turner Award for Research Impact.


Prof. Taylor reports the following:
  • Academic lectures funded by Eli Lilly and Janssen
  • Advisory work for Fast800
  • Member of ADA/EASD and DUK Consensus Committee on Remission of Type 2 Diabetes 2019-2021